6.1 Acute Kidney Injury (KDIGO Criteria), Glomerulonephritis, and CKD Management

Key Takeaways

  • Diagnose AKI using change in serum creatinine or reduced urine output over the stated time interval. Use the more severe of the two KDIGO staging criteria.

  • Assess perfusion, intrinsic disease and obstruction. Urinary indices support clinical reasoning but cannot establish a cause on their own.

  • Urgent kidney replacement therapy decisions depend on life-threatening electrolyte, acid–base, fluid, toxic or uraemic complications and their response to treatment.

  • Nephrotic syndrome features heavy proteinuria, hypoalbuminaemia and oedema, with increased thrombosis risk. Nephritic disease often presents with active urinary sediment, hypertension and declining kidney function.

  • Classify CKD by cause, eGFR and albuminuria. Individualise kidney-protective therapies, BP and monitoring. Use separate anaemia and mineral-bone recommendations.

Last updated: November 2026

KDIGO Definition and Staging of Acute Kidney Injury

Acute Kidney Injury (AKI) is an abrupt clinical syndrome characterized by a rapid decline in excretory renal function, leading to the accumulation of metabolic waste products (urea, creatinine) and failure of fluid, electrolyte, and acid-base homeostasis. Review the baseline, time course and urine output. Estimated GFR is unreliable for staging during a rapid creatinine change.

The KDIGO Diagnostic Criteria

Under the published 2012 KDIGO guideline, AKI is formally diagnosed by the presence of any one of the following three criteria:

  1. An absolute increase in serum creatinine of >= 26.5 mcmol/L (>= 0.3 mg/dL) within 48 hours; OR
  2. A relative increase in serum creatinine to >= 1.5x baseline, which is known or presumed to have occurred within the prior 7 days; OR
  3. A documented urine output of < 0.5 mL/kg/h for >= 6 consecutive hours.

KDIGO AKI Severity Staging

Once diagnosed, AKI is stratified into three distinct stages based on either the magnitude of serum creatinine elevation or the duration and severity of oliguria. The clinical stage assigned reflects the most severe parameter met:

KDIGO StageSerum Creatinine Elevation CriteriaUrine Output Criteria
Stage 11.5 to <2 times baseline OR absolute increase ≥26.5 µmol/L within 48 hours<0.5 mL/kg/h for 6 to <12 hours
Stage 22 to <3 times baseline< 0.5 mL/kg/h for >= 12 consecutive hours
Stage 3>= 3.0x baseline OR increase to >= 353.6 mcmol/L (>= 4.0 mg/dL) OR initiation of renal replacement therapy (RRT) OR in patients <18 years, a decrease in eGFR to <35 mL/min/1.73 m²< 0.3 mL/kg/h for >= 24 consecutive hours OR anuria for >= 12 consecutive hours

Important

The 'Triple Whammy' Prescribing Hazard: Simultaneous co-prescription of an ACE inhibitor (or ARB) + NSAID + Diuretic represents a common and preventable cause of severe iatrogenic AKI in acute medicine.

  • Diuretics deplete intravascular volume, reducing renal perfusion pressure.
  • NSAIDs inhibit renal cyclooxygenase (COX), blocking the compensatory synthesis of prostaglandin E2 and prostacyclin (PGI2), which normally maintain afferent arteriolar vasodilation. This can reduce afferent blood flow when perfusion is compromised.
  • ACE inhibitors / ARBs block angiotensin II-mediated vasoconstriction of the efferent arteriole, which can dilate the efferent arteriole. Together, these effects can lower glomerular filtration, especially during dehydration.

Worked example. Creatinine rises from 80 to 132 µmol/L in 36 hours, an increase of 52 µmol/L and 1.65 times baseline. That is stage 1 by creatinine. If urine output has been 0.4 mL/kg/h for 13 hours, assign stage 2 overall. Stage supports recognition and monitoring. Clinical complications determine emergency treatment.

KDIGO published AKI guideline · Study of ACEi/ARB, NSAID and diuretic use

Assess a child with possible acute kidney injury

Compare creatinine with an age-appropriate baseline and track urine output against weight and time. The published KDIGO criterion uses less than 0.5 mL/kg/hour for at least six hours, and the NICE NG148 detection pathway uses more than eight hours in children and young people. Each can detect AKI earlier if the creatinine criterion is met. Assess concerns as soon as they arise. Use separate neonatal criteria when applicable. Avoid interpreting an adult creatinine reference interval as normal for a small child.

Check perfusion and hydration, weight trend, blood pressure, fluid balance, urinalysis, creatinine and electrolytes. Consider dehydration, sepsis, medicines, obstruction and intrinsic disease. Oedema, hypertension and blood with protein in the urine suggest a glomerular process. After bloody diarrhoea, pallor or reduced urine output raises concern for haemolytic uraemic syndrome. Check haemoglobin, platelets and kidney function urgently. Involve paediatric and renal teams for AKI with haematuria, suspected glomerulonephritis, complications or worsening disease. Reassess after fluid intervention and review nephrotoxic medicines. Tailor follow-up to kidney recovery, blood pressure and residual proteinuria.

NICE NG148 AKI detection and follow-up · Children's Health Ireland haematuria guideline · Canadian Paediatric Society AKI statement · Children's Health Ireland bloody diarrhoea and HUS pathway

Determine the cause of AKI

Review fluid loss and intake, haemodynamics, infection, drugs and possible obstruction. Check urine output and dipstick promptly. Review prior creatinine, examine for hypovolaemia or congestion and arrange focused microscopy and imaging as indicated. More than one mechanism can be present.

1. Reduced perfusion

Haemorrhage, diarrhoea, vomiting and excess diuretic effect can reduce circulating volume. Sepsis, cirrhosis and heart failure can reduce effective renal perfusion, and venous congestion can contribute in heart failure. The autoregulatory pressure threshold varies. Restore perfusion by treating the mechanism. Give an isotonic crystalloid bolus with reassessment when clinically hypovolaemic, and treat congestion when fluid overload predominates.

2. Intrinsic disease

  • Acute tubular injury: May follow sustained hypoperfusion, sepsis or toxicity. Common clues include tubular epithelial cells or muddy-brown granular casts. Aminoglycosides, cisplatin and pigment from rhabdomyolysis or intravascular haemolysis are examples. Assess contrast-related risk before nonurgent studies and weigh the harm of delaying an emergency study.

Recognise rhabdomyolysis. Consider acute muscle injury in patients with new muscle pain, weakness or dark urine after prolonged immobilisation, severe exertion, a seizure, crush injury or a relevant drug exposure or interaction. Check creatine kinase (CK), creatinine, potassium and other electrolytes; obtain an ECG promptly if potassium may be high. A urine dipstick positive for blood with few or no red cells on microscopy supports pigment in this setting but cannot diagnose the cause alone. A compatible presentation with CK above five times the upper limit of normal is a common diagnostic definition. Follow CK and renal and electrolyte trends, remove the trigger, and give IV crystalloid when indicated with frequent review of perfusion, urine output and fluid balance. Treat dangerous hyperkalaemia promptly and seek renal or critical care input for deterioration or complications. Avoid routinely using bicarbonate or mannitol to prevent rhabdomyolysis-associated AKI.

AAST rhabdomyolysis consensus · HSE medicine management, statins.

  • Acute interstitial nephritis: Consider exposure to beta-lactams, PPIs or NSAIDs, and non-drug causes. Sterile pyuria, white-cell casts, fever, rash or eosinophilia can occur. A bland urine or negative urine eosinophils cannot exclude it. Stop a likely causative drug and involve nephrology if the diagnosis or recovery is uncertain. Biopsy may guide the decision about corticosteroids.
  • Glomerular, vascular or other disease: Haematuria with proteinuria, red-cell casts or dysmorphic red cells prompts assessment for nephritis, especially with rising creatinine or systemic findings. In compatible presentations, consider vasculitis, thrombotic microangiopathy or myeloma.

3. Obstruction

Check whether the bladder is full or an existing catheter is blocked. Causes include prostate enlargement, strictures, neurogenic bladder, bilateral stones or malignant ureteric obstruction. A solitary functioning kidney can become acutely impaired with unilateral obstruction. A normal early ultrasound can miss obstruction when clinical suspicion remains high.

NICE NG148 advises ultrasound within six hours for suspected pyonephrosis and within 24 hours for unexplained AKI or obstruction risk. Infected obstruction, an obstructed solitary kidney, bilateral upper-tract obstruction and obstruction with AKI complications need immediate urological input. Lower-tract retention usually needs catheter drainage. Upper-tract obstruction may require stenting or nephrostomy. Monitor for post-obstructive diuresis after relief.

Interpret urinary indices with the clinical findings

FindingSupports reduced perfusionSupports tubular injury
Urinary sodium, fractional excretion of sodium (FeNa)Low urine sodium or FeNa <1% can reflect sodium retentionHigher values may occur with impaired reabsorption
Urine concentrationConcentrated urine can support intact concentrating abilityLoss of concentrating ability may produce urine near plasma osmolality
Urine sedimentBland or hyaline casts may occurTubular epithelial cells and coarse granular casts increase suspicion

Calculate FeNa=100×UNa×SCrSNa×UCr\mathrm{FeNa} = 100 \times \frac{U_{\mathrm{Na}}\times S_{\mathrm{Cr}}}{S_{\mathrm{Na}}\times U_{\mathrm{Cr}}} using matching units for urine and serum concentrations. Diuretics, CKD, sepsis and mixed injury can change the result. Fractional excretion of urea may add context, but it can also mislead. Neither index establishes the diagnosis or excludes obstruction. Reassess the history, sediment and response to treatment. Agree which medicines to hold during acute illness and when to restart indicated therapy.

KDIGO AKI · NICE AKI recommendations · Urine microscopy study · Biopsy-based urine eosinophil study

Recognise urgent kidney replacement therapy indications

Start emergency treatment while contacting renal and critical-care teams. Use AEIOU to recall important complications. KDIGO and NICE base the decision on the clinical problem, trend and response to treatment.

ComplicationWhy it may require urgent replacement therapy
A – AcidosisSevere metabolic acidosis persisting despite appropriate treatment of the cause and feasible support. Use the pH trend, ventilation, haemodynamics and available options.
E – ElectrolytesSevere hyperkalaemia that persists or recurs despite appropriate temporising measures, or cannot be controlled safely. ECG toxicity warrants immediate cardiac protection.
I – IngestionSelected severe poisoning with a dialysable agent, such as lithium, methanol, ethylene glycol or salicylate. Check the toxin-specific indications with toxicology and nephrology.
O – OverloadPulmonary oedema or other serious fluid overload that cannot be controlled safely with medical treatment.
U – UraemiaComplications such as pericarditis or encephalopathy. Assess a pericardial effusion for tamponade and obtain emergency specialist drainage if tamponade is present.

Oliguria and rapidly worsening results increase urgency. Creatinine and urea concentrations alone do not establish the indication. Intermittent and continuous therapies are chosen according to the patient’s condition, access and local capabilities.

Hyperkalaemia in AKI

  1. Protect the heart. Get ECG monitoring and treat hyperkalaemic ECG toxicity promptly. The HSE safety alert gives equivalent calcium doses of 30 mL of 10% gluconate and 10 mL of 10% chloride, about 6.8 mmol of calcium. Follow the local pathway for salt selection and check the ECG response. UKKA gives gluconate over ten minutes outside resuscitation and prefers chloride in peri-arrest or arrest. In hyperkalaemic cardiac arrest, ERC 2025 gives 10 mL of 10% calcium chloride IV and 50 mmol IV sodium bicarbonate through separate lines or with a flush between them.
  2. Shift potassium. UKKA uses 10 units soluble insulin with 25 g IV glucose in severe hyperkalaemia. For example, 125 mL of 20% glucose supplies 25 g. Use the local formulation and monitor glucose closely for at least six hours. Nebulised salbutamol can supplement insulin. Routine bicarbonate is not part of the non-arrest hyperkalaemia pathway.
  3. Remove potassium. Arrange definitive removal early when kidney excretion is inadequate. A binder may help in selected patients and does not replace urgent dialysis. Recheck potassium and watch for rebound. See the electrolyte section for the monitoring schedule and glucose supplementation threshold.

HSE calcium safety alert · UKKA acute hyperkalaemia · ERC special circumstances · NICE AKI recommendations

Distinguish nephrotic and nephritic presentations

FeaturePredominantly nephroticPredominantly nephritic
UrineHeavy protein loss, often without visible blood. Lipiduria may be present.Haematuria, dysmorphic red cells or red-cell casts, with variable proteinuria
Clinical patternHypoalbuminaemia and oedema. Hyperlipidaemia is common.Hypertension, oedema, oliguria or rising creatinine
PrioritiesQuantify protein loss, assess cause and check for thrombosis and infection.Identify rapidly progressive disease and systemic causes. Request urgent renal assessment when appropriate.

An adult with protein excretion above 3.5 g/day, low albumin and oedema has the classic nephrotic picture. Spot PCR or ACR can help quantify protein loss. They measure different analytes, and the ratio and a timed measurement are not interchangeable in every patient. Some glomerular disorders produce both nephrotic and nephritic features.

Nephrotic causes and complications

  • Minimal change disease: The usual pattern is little visible change on light microscopy and diffuse podocyte foot-process effacement on electron microscopy. Adult diagnosis generally requires biopsy. Most typical childhood presentations initially follow the separate paediatric pathway. Corticosteroid response is common, with age-specific regimens and time courses.
  • Focal segmental glomerulosclerosis: A biopsy pattern in which segments of some glomeruli are scarred. Primary, genetic and secondary forms have different treatment implications. Consider HIV, obesity, reduced nephron mass and genetic susceptibility, including APOL1-associated risk in appropriate patients.
  • Membranous nephropathy: Subepithelial deposits cause capillary wall changes. Anti-PLA2R supports PLA2R-associated membranous nephropathy, and KDIGO allows diagnosis without confirmatory biopsy in typical nephrotic patients with positive anti-PLA2R. Evaluate for associated conditions, including hepatitis, lupus, medicines and malignancy as clinically appropriate.
  • Thrombosis: Urinary loss of anticoagulant proteins and changes in clotting factors and platelets contribute to risk, particularly in membranous nephropathy. Acute flank pain, haematuria and deteriorating kidney function raise concern for renal vein thrombosis and warrant urgent imaging. Decide on prophylaxis using disease-specific thrombosis risk, albumin assay and bleeding risk. A single albumin value does not mandate LMWH.
  • Infection and dyslipidaemia: Urinary protein losses and immunosuppressive therapy can increase infection risk. Hyperlipidaemia and lipiduria can accompany the syndrome.

KDIGO glomerular disease · KDIGO childhood nephrotic syndrome

Nephritic and rapidly progressive glomerular disease

ConditionRecognise the patternWorkup and management
Post-streptococcal GNOedema, haematuria and hypertension after a latent interval. Typically about ten days after pharyngitis or up to about three weeks after skin infection. C3 is usually low.Look for evidence of recent group A strep, such as ASO or anti-DNase B. Manage fluid and BP and eradicate residual strep. Reassess persistent low complement, atypical findings or worsening kidney function.
IgA nephropathyVisible haematuria can occur during or soon after an upper respiratory infection. Serum complement is usually normal. IgA vasculitis can add purpura, joint and gastrointestinal symptoms.Renal biopsy shows dominant or codominant mesangial IgA. Use maximally tolerated ACEi or ARB where indicated, address BP and proteinuria, and consider an SGLT2 inhibitor in appropriate at-risk patients. Discuss targeted therapy such as targeted-release budesonide with specialists where eligible.
ANCA-associated GNRising creatinine with active sediment. GPA may include sinus disease or lung nodules. GPA often associates with PR3 and MPA often with MPO, but neither antibody defines all cases. Pulmonary haemorrhage can occur.Send PR3/MPO and other relevant tests, obtain urgent renal input and plan biopsy. Pauci-immune necrotising or crescentic GN is typical. Induction often uses rituximab or cyclophosphamide with a glucocorticoid regimen. Plasma exchange is reserved for selected circumstances.
Anti-GBM diseaseRapidly progressive GN, with or without pulmonary haemorrhage.Send anti-GBM antibody testing urgently. Linear IgG along the GBM supports the diagnosis. Discuss prompt plasma exchange, glucocorticoids and cyclophosphamide. KDIGO identifies an exception for some dialysis-dependent presentations with severe irreversible biopsy findings and no lung haemorrhage.

Timing and complement help to distinguish IgA nephropathy from post-infectious disease but do not establish either alone. Rapid loss of function, red-cell casts or haemoptysis with active sediment calls for urgent investigation. In a high-probability pulmonary–renal syndrome, the specialist team may start treatment before biopsy results. The EU marketing authorisation for avacopan was revoked in August 2026, superseding its option in the older ANCA guidance for Irish practice.

CDC post-streptococcal GN · KDIGO glomerular guideline updates · EMA avacopan decision

Chronic Kidney Disease (CKD): Staging, Progression Prevention, and Mineral/Bone Disorder

Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function present for at least three months, with implications for health. The KDIGO classification combines estimated glomerular filtration rate (eGFR, categories G1–G5) and albuminuria (categories A1–A3) to predict mortality and progression.

The KDIGO Heat Map: Staging Framework

eGFR Categories (mL/min/1.73m2):
-> G1: >= 90 (Normal or high GFR)
-> G2: 60 - 89 (Mildly decreased kidney function)
-> G3a: 45 - 59 (Mildly to moderately decreased)
-> G3b: 30 - 44 (Moderately to severely decreased)
-> G4: 15 - 29 (Severely decreased kidney function)
-> G5: < 15 (Kidney failure)

Albuminuria Categories (Urine Albumin:Creatinine Ratio [ACR]):
-> A1: < 3 mg/mmol (< 30 mg/g) - Normal to mildly increased
-> A2: 3 - 30 mg/mmol (30 - 300 mg/g) - Moderately increased
-> A3: > 30 mg/mmol (> 300 mg/g) - Severely increased

G1 and G2 require another marker of kidney damage to establish CKD. Use cause, GFR and albuminuria together. Establish chronicity from prior values, repeat measurements, imaging or other evidence, and interpret eGFR only when creatinine is sufficiently stable. For example, persistent eGFR 38 with ACR 45 mg/mmol is G3b A3. It carries greater risk than the same eGFR with A1 albuminuria. In G3–G5, a validated kidney failure risk equation can support referral and planning.

Slowing progression and reducing cardiovascular risk

  1. Blood pressure: Use standardised measurement and individualise targets for tolerance, frailty and postural symptoms. KDIGO suggests standardised office systolic BP <120 mmHg when tolerated for adults with high BP and CKD who are not on dialysis. The 2026 ESC/ERA CKD guideline targets 120–129 mmHg if tolerated in CKD with eGFR ≥30 to reduce cardiovascular risk and albuminuria.
  2. ACE inhibitor or ARB: KDIGO recommends or suggests treatment according to diabetes and albuminuria category, including A2–A3 with diabetes and stronger evidence in A3 without diabetes. Avoid combining an ACE inhibitor and an ARB. Check BP, creatinine and potassium in two to four weeks after initiation or dose increase, sooner when risk warrants. A rise above 30% within four weeks triggers review for causes such as volume depletion or interacting drugs. Consider dose reduction for symptomatic hypotension or hyperkalaemia that remains uncontrolled.
  3. SGLT2 inhibitors: KDIGO recommends for T2D with CKD at eGFR ≥20, for adults with CKD and eGFR ≥20 plus ACR ≥20 mg/mmol, or in heart failure irrespective of albuminuria. It suggests use at eGFR 20–45 with lower ACR. Check the specific product. For CKD, the usual dose is 10 mg daily, but the EU Forxiga label does not recommend starting below GFR 25 mL/min and Jardiance does not recommend starting below eGFR 20 mL/min/1.73 m². Review perioperative and acute illness withholding separately.
  4. Finerenone: Consider for selected adults with T2D, albuminuric CKD despite maximally tolerated RAS blockade and acceptable eGFR and potassium. Under the EU CKD indication, initiation is not recommended at eGFR <25 or potassium >5.0 mmol/L. Check the label for dose, enhanced monitoring at borderline potassium and the four-week review.

CKD complications

  • Anaemia. Reduced erythropoietin and inflammation-related iron restriction contribute. Check blood count, reticulocytes, ferritin and TSAT and investigate other causes, including bleeding as indicated. KDIGO 2026 suggests initiating iron in haemodialysis when ferritin ≤500 µg/L and TSAT ≤30%, usually IV. For non-haemodialysis CKD, it suggests iron when ferritin <100 µg/L with TSAT <40%, or ferritin 100 to <300 µg/L with TSAT <25%. Select oral or IV treatment for non-haemodialysis patients according to severity, response, tolerability and preferences. Address reversible causes before an ESA and individualise initiation. When using an ESA in adults, target Hb below 115 g/L. Higher-target trials showed adverse outcomes, including excess stroke in TREAT.
  • Mineral and bone disorder. Reduced renal calcitriol synthesis and altered phosphate handling can contribute to secondary hyperparathyroidism. Review serial calcium, phosphate and PTH together. Treat persistently elevated phosphate and limit calcium-based binder exposure where used. In non-dialysis CKD, address modifiable factors and reserve active vitamin D for selected severe progressive hyperparathyroidism. In dialysis, specialist options include calcimimetics and active vitamin D agents.
  • Follow-up. Reassess after AKI for recovery or CKD. In established CKD, monitor progression and drug safety, address cardiovascular risk and arrange renal referral for significant progression, high failure risk, major albuminuria or complications as appropriate.

KDIGO CKD 2024 · ESC/ERA CKD 2026 · KDIGO anaemia 2026 · KDIGO CKD-MBD · Forxiga EU label · Jardiance EU label · Kerendia EU label

Recognise chronic kidney disease in children

Use growth, blood pressure, prior results and a validated age-appropriate equation to assess kidney function. In children over two, KDIGO flags creatinine-based eGFR below 90 mL/min/1.73 m² as potentially low. A single estimate does not determine chronicity. Repeat abnormal tests and look for persistent markers such as albuminuria, haematuria or a urinary tract abnormality. For example, persistent ACR of at least 3 mg/mmol on repeat first-morning specimens when well, sustained loss of eGFR or hypertension supports referral for paediatric renal assessment. Consider structural causes and inherited disease where appropriate. Follow growth and nutrition, and plan transfer to adult services with the young person and both teams. Do not use the adult kidney failure risk equation to decide whether to refer a child.

Before elective surgery in a patient with CKD, communicate usual kidney function, recent potassium and volume status, medicines and, if relevant, the dialysis plan. Discuss perioperative medication and fluid management with the responsible teams. Check for new AKI or electrolyte complications before proceeding when the patient has deteriorated.

KDIGO 2024, practice points 1.2.3.5 and 5.1.2 · HSE paediatric nephrology model.

Loading diagram...
KDIGO Acute Kidney Injury Diagnostic and Management Pathway
Test Your Knowledge

A 72-year-old man with a history of hypertension, type 2 diabetes mellitus, and osteoarthritis presents to the acute medical unit with a 4-day history of severe vomiting, profuse watery diarrhoea, and inability to maintain oral intake. His current outpatient medications include lisinopril 20 mg once daily, indomethacin 50 mg twice daily, and furosemide 40 mg once daily. On examination, he is lethargic with dry mucous membranes, a blood pressure of 94/56 mmHg, and a heart rate of 110 beats/min. His baseline serum creatinine 5 days ago was 82 mcmol/L. Today's blood investigations demonstrate: serum sodium 134 mmol/L, potassium 5.2 mmol/L, urea 24.8 mmol/L, and serum creatinine 294 mcmol/L. Urinalysis shows no protein, no blood, and no leukocytes, with a specific gravity of 1.028. Spot urinary electrolytes reveal a urine sodium of 11 mmol/L, and the calculated fractional excretion of sodium (FeNa) is 0.4%. What is the primary underlying mechanism of this patient's acute kidney injury, and what is the most appropriate initial management?

A

Acute interstitial nephritis induced by indomethacin; initiate oral prednisolone 1 mg/kg daily and arrange an urgent percutaneous renal biopsy

B

Hypoperfusion from gastrointestinal losses compounded by the ACE inhibitor, NSAID and diuretic. Hold the contributing drugs during acute hypovolaemia and give reassessed IV isotonic crystalloid.

C

Acute tubular necrosis caused by prolonged ischemic injury; initiate emergency continuous venovenous haemodiafiltration and administer intravenous sodium bicarbonate

D

Post-renal obstructive uropathy due to benign prostatic hyperplasia; insert an irrigating three-way urinary catheter and perform emergent abdominal computed tomography

Test Your Knowledge

A 64-year-old woman with known stage 4 chronic kidney disease presents to the emergency department with severe progressive breathlessness, orthopnoea, and nausea over the past 48 hours. On examination, she is tachypnoeic at 28 breaths/min with bilateral coarse inspiratory crackles extending throughout both mid- and lower lung zones. Blood pressure is 174/98 mmHg, heart rate is 96 beats/min, and auscultation of the precordium reveals a harsh, scratchy, triphasic friction rub heard loudest at the left sternal border with the patient leaning forward. Arterial blood gas on room air shows: pH 7.21, PaCO2 3.8 kPa, PaO2 10.4 kPa, and HCO3 11 mmol/L. Serum laboratory results demonstrate: potassium 6.9 mmol/L, urea 44.0 mmol/L, and serum creatinine 710 mcmol/L (baseline 230 mcmol/L). The 12-lead ECG demonstrates tall, symmetrical, peaked T waves and broad, widened QRS complexes (134 ms). She is immediately administered intravenous 10% calcium gluconate and insulin-dextrose. The renal team is contacted during initial treatment. Potassium remains 6.9 mmol/L despite temporising therapy, and severe pulmonary oedema persists despite ventilatory support and IV loop diuretic treatment. Urine output remains minimal. Bedside echocardiography shows no tamponade. Which of the following is the most definitive and appropriate next step in management?

A

Administer oral sodium zirconium cyclosilicate 10 g and re-evaluate serum electrolytes in 6 hours

B

Initiate an intravenous infusion of 1.26% sodium bicarbonate at 250 mL/h to correct severe metabolic acidaemia

C

Arrange immediate kidney replacement therapy with the renal and critical-care teams, continuing temporising treatment while access is secured.

D

Perform immediate emergency bedside pericardiocentesis under subxiphoid ultrasound guidance

Test Your Knowledge

A 52-year-old man presents with progressive bilateral lower extremity swelling, facial puffiness, and abdominal distension over the past month. Physical examination demonstrates pitting oedema extending to the mid-thighs, shifting dullness in the abdomen, and blood pressure 136/84 mmHg. Dipstick urinalysis demonstrates 4+ protein and no blood. A 24-hour urine collection confirms 8.2 g of protein, and urine protein:creatinine ratio (PCR) is 680 mg/mmol. Laboratory testing reveals: serum albumin 18 g/L, total cholesterol 10.4 mmol/L, and serum creatinine 88 mcmol/L. Serum anti-PLA2R antibodies return strongly positive at a high titre. While in the acute medical unit awaiting specialist nephrology review, the patient develops sudden-onset, severe right loin and flank pain, gross macroscopic haematuria, and an acute rise in serum creatinine to 174 mcmol/L. What is the most likely acute complication explaining this sudden deterioration, and what is its primary pathophysiological mechanism?

A

Acute renal vein thrombosis due to nephrotic hypercoagulability

B

Acute post-streptococcal glomerulonephritis triggered by subepithelial immune complex deposition following an unrecognised streptococcal infection

C

Acute interstitial nephritis precipitated by statin therapy and myoglobin deposition within the proximal tubules

D

Spontaneous bacterial peritonitis caused by urinary loss of complement factor B and bacterial translocation across the gut mucosa

Test Your Knowledge

A 7-year-old has markedly reduced urine output, new pallor and tiredness several days after bloody diarrhoea. Creatinine has risen from 35 to 75 µmol/L since yesterday and the platelet count is 72 × 10⁹/L. What is the best next step?

A

Arrange urgent paediatric and renal assessment for possible haemolytic uraemic syndrome, including investigation for haemolysis and close monitoring of kidney function and fluid status

B

Treat the diarrhoea with loperamide and review the kidney results next week

C

Exclude kidney injury because creatinine is below a common adult upper reference limit

D

Treat as uncomplicated dehydration and discharge as soon as the child accepts a drink

Test Your Knowledge

An adult taking simvastatin develops severe diffuse muscle pain, weakness and dark urine after being prescribed clarithromycin. Creatinine has risen, urine dipstick registers blood, and microscopy shows very few red cells. What is the most appropriate initial action?

A

Assess urgently for rhabdomyolysis, stop the suspected contributing drug combination, and check CK, renal function, potassium and ECG

B

Interpret the result as uncomplicated cystitis and prescribe an antibiotic without further tests

C

Continue both medicines and check CK after symptoms resolve

D

Treat the positive dipstick as proof of glomerulonephritis and start steroids

Test Your Knowledge

A clinically well 11-year-old has an eGFR of 76 mL/min/1.73 m² by a validated paediatric equation, repeatedly documented four months apart. First-morning urine ACR is 5 mg/mmol on two occasions while well, and blood pressure has been persistently above the appropriate paediatric range. What is the next step?

A

Discharge from follow-up because eGFR is above 60

B

Refer to paediatric nephrology and assess the cause and trajectory of the kidney findings

C

Wait for an adult kidney failure risk estimate before arranging referral

D

Arrange emergency dialysis solely because eGFR is below 90

Sections you finish are checked off in the contents.